Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cells for Liver Disease: Fibrosis and Inflammation
Transcript
- 0:00SPEAKER_01: If you surgically cut away up to 70% of a perfectly healthy human liver, it will not just sit there functioning at 30% capacity.
- 0:08SPEAKER_01: It will completely regrow itself to its full original size.
- 0:12SPEAKER_00: It is truly a biological superpower.
- 0:15SPEAKER_01: I mean, you you just do not see the human heart or the brain doing anything remotely like that.
- 0:21SPEAKER_00: But what happens when that superpower breaks?
- 0:23SPEAKER_00: When the damage is so relentless that the organ's natural repair kit basically just gives up.
- 0:28SPEAKER_01: Welcome to the Serano Cell Podcast.
- 0:30SPEAKER_01: We are setting out on a very specific mission for you today.
- 0:34SPEAKER_00: We are diving into the experimental frontier of treating chronic liver disease.
- 0:38SPEAKER_00: Specifically, we're unpacking an article on stem cells, fibrosis, and inflammation.
- 0:43SPEAKER_01: And the goal here is to completely separate the exciting theoretical science from the grounded clinical reality.
- 0:50SPEAKER_01: Zero hype, just what the data actually says.
- 0:53SPEAKER_00: Because researchers are heavily focused on mesenchymal stem cell therapy right now, trying to see if it could theoretically shift that balance back in the liver's favor when it's failing.
- 1:03SPEAKER_01: And we really need to define what that actually means because it sounds incredibly dense on paper.
- 1:08SPEAKER_00: Put simply, those are multipotent adult stem cells.
- 1:12SPEAKER_00: So unlike embryonic stem cells that can become any tissue, these are found in places like bone marrow or fat or umbilical cord tissue.
- 1:20SPEAKER_01: And they usually specialize in making skeletal tissues like bone or cartilage.
- 1:24SPEAKER_01: But researchers found they have this fascinating secondary skill.
- 1:27SPEAKER_01: They are incredibly good at managing the immune system.
- 1:29SPEAKER_00: Aaron Powell Yes, and responding to tissue inflammation.
- 1:32SPEAKER_00: But before we get into the fix, we really need to understand how the liver's repair system breaks down in the first place.
- 1:38SPEAKER_01: Aaron Ross Powell Because if you're listening, you might picture liver damage as one sudden catastrophic event, like a poisoning, but it's actually a very slow, silent burn.
- 1:47SPEAKER_00: Aaron Powell Imagine someone in their 30s who contracts hepatitis C or maybe develops fatty liver disease.
- 1:53SPEAKER_00: For a decade, they might not feel a single thing.
- 1:55SPEAKER_01: Aaron Powell The National Institute of Diabetes and Digestive and Kidney Diseases, the N I DK, defines this as early fibrosis, and it is entirely silent.
- 2:05SPEAKER_01: You can have this building up and experience zero symptoms.
- 2:09SPEAKER_00: What's fascinating here is the biological progression from that early silent scarring to irreversible damage.
- 2:15SPEAKER_00: Fibrosis is just the medical term for excess scar tissue, and it's driven by long-lasting inflammation.
- 2:21SPEAKER_01: So under normal conditions, uh small injury happens and the liver heals it cleanly.
- 2:26SPEAKER_00: But with a chronic trigger like hepatitis B or C or heavy alcohol use over many years, or an autoimmune condition, the immune system is kept in a state of chronic alarm.
- 2:35SPEAKER_00: It never gets the signal to stand down.
- 2:37SPEAKER_01: I think we need a visual for this.
- 2:39SPEAKER_01: Think of the liver like a heavily trafficked supply road in a major city.
- 2:44SPEAKER_01: When a minor injury happens, uh, it's like a single pothole.
- 2:47SPEAKER_00: The repair crews come out, patch it up, and traffic keeps moving.
- 2:51SPEAKER_01: Exactly.
- 2:51SPEAKER_01: Uh the organ keeps filtering toxins normally.
- 2:54SPEAKER_01: But chronic liver disease is not a single pothole.
- 2:57SPEAKER_01: It is like having daily, continuous earthquakes on that road for 20 or 30 years.
- 3:03SPEAKER_00: The repair crews completely panic.
- 3:05SPEAKER_01: They do.
- 3:05SPEAKER_01: Instead of carefully patching holes, they just start pouring emergency concrete everywhere to try and stabilize the ground.
- 3:11SPEAKER_01: And in the liver, that emergency concrete is scar tissue.
- 3:15SPEAKER_00: And that biological concrete pouring leads to the later stages on the NIDDK's path, which is cirrhosis, permanent, heavy scarring.
- 3:23SPEAKER_01: The soft, filtering tissue is replaced by this stiff, non-functioning scar tissue, which is deadly because blood can't flow through it easily anymore.
- 3:32SPEAKER_00: Pressure builds up in the veins.
- 3:33SPEAKER_00: Toxins that the liver normally filters out start backing up into the bloodstream and they can eventually reach the brain.
- 3:39SPEAKER_01: So the end game here is advanced cirrhosis progressing to end-stage liver disease.
- 3:44SPEAKER_01: At that point, a liver transplant becomes the main option to save a patient's life.
- 3:49SPEAKER_00: So the daily earthquakes trigger the concrete, which eventually ruins the entire road network.
- 3:54SPEAKER_01: Aaron Powell, which brings up a massive question.
- 3:56SPEAKER_01: If the immune system is stuck in this destructive loop, how do you send a signal strong enough to tell it to just stop?
- 4:04SPEAKER_00: That is the exact question driving the current stem cell research, but we have to fundamentally shift how we think about stem cells first.
- 4:11SPEAKER_00: Historically, people thought of them as replacement parts.
- 4:13SPEAKER_01: Aaron Powell Like swapping out the bad concrete for fresh asphalt.
- 4:17SPEAKER_01: You inject the cells and they physically turn into new liver cells.
- 4:20SPEAKER_00: Aaron Powell But from the literature, that is not what the current science suggests at all.
- 4:25SPEAKER_00: Researchers now believe these introduced stem cells act more like biological managers or signal callers.
- 4:32SPEAKER_01: A 2022 review of liver cell therapies outlines three specific mechanisms for this.
- 4:37SPEAKER_01: First, they seem to interact directly with the overactive immune cells.
- 4:41SPEAKER_00: Aaron Powell They effectively send a chemical signal trying to turn off the alarm bell.
- 4:46SPEAKER_00: And second, they target a very specific cell in the liver called a hepatic stellate cell.
- 4:51SPEAKER_01: Aaron Powell Those are the concrete pores in our road analogy.
- 4:54SPEAKER_00: They usually sit quietly in a healthy liver storing vitamin A, but chronic damage activates them.
- 5:00SPEAKER_00: They lose their vitamin A and start churning out collagen, which makes the scar tissue.
- 5:05SPEAKER_01: So the stem cells theoretically send signals to deactivate those stellate cells.
- 5:10SPEAKER_01: And the third mechanism is the release of extracellular vesicles.
- 5:15SPEAKER_00: Which is a highly sophisticated method of cellular communication.
- 5:19SPEAKER_01: I love this concept.
- 5:20SPEAKER_01: If a cell is a manufacturing factory, an extracellular vesicle is like a tiny microscopic shipping container.
- 5:27SPEAKER_01: The stem cells release these packets filled with chemical instructions and genetic material called microRNAs.
- 5:34SPEAKER_00: They float over to the struggling native liver cells, enter them, and deliver this genetic care package.
- 5:40SPEAKER_00: It turns survival genes on and inflammatory genes off.
- 5:44SPEAKER_01: It's the body's internal messaging system.
- 5:47SPEAKER_01: And to give you some context on how this theoretical science intersects with the real world, we can look at Sarona cell.
- 5:54SPEAKER_00: They are a regenerative medicine center in Kuala Lumpur.
- 5:58SPEAKER_01: Yes, serving local and international patients through partner facilities.
- 6:02SPEAKER_01: They state their treatments utilize Wharton's jelly-derived mesenchymal stem cells from umbilical cord tissue.
- 6:09SPEAKER_01: Wharton's jelly is just the gelatinous substance in the umbilical cord that insulates the vessels, and it's very rich in these cells.
- 6:16SPEAKER_00: But we need to draw a very clear boundary here.
- 6:19SPEAKER_00: While facilities might use Wharton's jelly from umbilical cord tissue, the major clinical trials we're about to discuss actually used bone marrow cells.
- 6:27SPEAKER_01: Aaron Powell That is a crucial distinction.
- 6:29SPEAKER_00: Aaron Powell It is.
- 6:30SPEAKER_00: The source article explicitly states that no single cell source is proven for liver disease yet.
- 6:35SPEAKER_00: So whether it's bone marrow, fat, or umbilical cord tissue, the medical community does not have definitive proof that any of them are effective for liver disease.
- 6:44SPEAKER_01: Aaron Powell Okay.
- 6:45SPEAKER_01: Let's unpack this because most of the evidence for those three actions, the immune calming, the vesicles, comes from lab and animal work.
- 6:54SPEAKER_01: And there is a glaring timeline problem here.
- 6:56SPEAKER_00: Aaron Ross Powell The translation from mice to humans?
- 6:59SPEAKER_01: Aaron Powell Right.
- 6:59SPEAKER_01: I mean, in an animal experiment, researchers might induce liver injury in a mouse using a toxin.
- 7:05SPEAKER_01: The mouse gets sick in a matter of weeks.
- 7:07SPEAKER_01: They give the stem cells and see incredible results.
- 7:10SPEAKER_00: Aaron Powell But human liver disease builds over decades.
- 7:12SPEAKER_00: A human liver inflamed by 30 years of alcohol use is a completely different biological landscape than a mouse injured three weeks ago.
- 7:19SPEAKER_01: Aaron Powell Does this massive timeline difference mean animal results might just fail when they hit a deeply scarred human organ?
- 7:26SPEAKER_00: Aaron Powell It is arguably the biggest hurdle in this research.
- 7:29SPEAKER_00: The fibrotic tissue in humans is deeply established.
- 7:32SPEAKER_00: It has altered the physical architecture of the organ.
- 7:35SPEAKER_01: Aaron Powell So we have to look at the human trials to see what happens when the theory meets a real human liver.
- 7:42SPEAKER_01: The reading details three specific small trials.
- 7:45SPEAKER_00: Aaron Powell Let's start with the 2016 trial.
- 7:48SPEAKER_00: This focused on alcohol-related cirrhosis and involved 72 people.
- 7:53SPEAKER_01: And they used their own bone marrow cells for this one.
- 7:56SPEAKER_00: Aaron Powell They did.
- 7:57SPEAKER_00: And the reported result was that at the 12-month mark, liver biopsies showed less scarring in the group that received the cells.
- 8:04SPEAKER_01: Aaron Powell But how does a doctor actually measure less scarring?
- 8:07SPEAKER_01: Do they just pull out a piece of liver to look at?
- 8:10SPEAKER_00: Aaron Powell Essentially, yes.
- 8:11SPEAKER_00: A biopsy takes a tiny core sample of the tissue.
- 8:14SPEAKER_00: Pathologists use specialized scoring systems under a microscope to quantify the percentage of healthy cells versus collagen.
- 8:21SPEAKER_01: Aaron Powell So seeing a physical reduction suggests the concrete pouring might have slowed down.
- 8:26SPEAKER_01: That's an encouraging early sign.
- 8:27SPEAKER_00: Aaron Powell Then we move to the 2017 trial involving 110 people.
- 8:31SPEAKER_00: These patients had liver failure specifically linked to hepatitis B.
- 8:35SPEAKER_01: Aaron Ross Powell And in this case they use donor bone marrow cells, not the patient's own cells.
- 8:40SPEAKER_01: Why the switch?
- 8:41SPEAKER_01: This is just to save time?
- 8:42SPEAKER_00: Aaron Ross Powell Time is definitely a factor with liver failure, as harvesting a patient's own cells takes weeks.
- 8:48SPEAKER_00: But there is also a biological theory that a patient with end stage disease might have exhausted or compromised stem cells.
- 8:55SPEAKER_01: Aaron Powell So healthy donor cells might provide a more robust manager.
- 8:59SPEAKER_00: Aaron Powell That's the idea.
- 9:01SPEAKER_00: And in this 2017 trial, they tracked survival rates at 24 weeks.
- 9:06SPEAKER_00: The group receiving the cells had a 73.2% survival rate compared to 55.6% in the control group.
- 9:14SPEAKER_01: Aaron Powell A nearly 20% difference in survival at six months is a massive win for liver failure.
- 9:20SPEAKER_01: When I read that, it sounded like an absolute breakthrough.
- 9:23SPEAKER_00: But then you hit the 2021 trial.
- 9:25SPEAKER_01: Aaron Powell Exactly.
- 9:26SPEAKER_01: It felt like a gut punch.
- 9:28SPEAKER_01: This trial had a much longer follow-up period that followed 219 people with liver failure for up to 75 months over six years.
- 9:35SPEAKER_00: Aaron Powell And the result of that long-term tracking was no difference in liver cancer-free survival between the groups.
- 9:42SPEAKER_01: So I have to ask, if the 2021 study with the longest follow-up showed no difference, does that cancel out the 2016 and 2017 results?
- 9:52SPEAKER_01: Or does it just mean the effects wear off?
- 9:55SPEAKER_00: That is the pivotal question.
- 9:57SPEAKER_00: A 2020 pooled review tried to combine several small trials to get a broader picture and found some short-term gains.
- 10:04SPEAKER_00: But pooling small trials introduces a major statistical problem.
- 10:08SPEAKER_00: You end up pooling their inherent weaknesses.
- 10:11SPEAKER_01: So for someone who isn't a statistician, it's like having five small cups of muddy water.
- 10:16SPEAKER_01: If you pour them all into one giant bucket, you don't get clear water, you just get a larger bucket of mud.
- 10:22SPEAKER_00: That is an excellent way to put it.
- 10:23SPEAKER_00: And the structural flaws in these early trials are profound.
- 10:27SPEAKER_00: Many lacked a dummy treatment group or a placebo group.
- 10:31SPEAKER_01: Because of the 2016 trial, used a patient's own bone marrow, to have a true dummy group, you'd have to drill into a control patient's hip bone just to pretend to extract marrow.
- 10:41SPEAKER_00: The ethical dilemma of sham surgeries is incredibly difficult to navigate with severely ill patients.
- 10:47SPEAKER_00: So the trials were unblinded.
- 10:49SPEAKER_00: The doctors and the patients knew who got the cells.
- 10:52SPEAKER_01: Meaning just the psychological hope of getting an experimental treatment could have skewed the liver survival data.
- 10:58SPEAKER_00: Aaron Powell It absolutely can change physical behavior.
- 11:01SPEAKER_00: A patient might adhere more strictly to their diet or avoid alcohol better.
- 11:06SPEAKER_00: And a doctor might subconsciously monitor that patient closer, catching other minor infections earlier.
- 11:11SPEAKER_01: Aaron Powell Making it mathematically impossible to separate the true biological effect of the stem cells from the benefits of simply receiving extra medical attention.
- 11:19SPEAKER_00: And regarding the long-term data, the 2017 trial only tracked survival for 24 weeks.
- 11:25SPEAKER_00: We have no idea what happened to those patients at year three.
- 11:28SPEAKER_00: The 2021 trial strongly suggests any early boost doesn't permanently alter the long-term trajectory.
- 11:34SPEAKER_01: Which forces a very heavy reality check.
- 11:37SPEAKER_01: If you're listening, you're probably wondering where this leaves a patient today.
- 11:40SPEAKER_01: And we have to look closely at the risks.
- 11:59SPEAKER_01: A fever could signal a severe infection that their failing liver simply cannot handle.
- 12:04SPEAKER_00: The 2022 review also highlights that infused cells may not actually survive very long in the human body.
- 12:09SPEAKER_01: So they aren't setting up a permanent camp in the liver to supervise those repair crews.
- 12:14SPEAKER_00: The evidence suggests they deliver their signals, release their vesicles, and then quickly die off within days or weeks.
- 12:20SPEAKER_00: Meaning you might need repeated infusions over years to maintain that signal.
- 12:24SPEAKER_01: And we currently have zero data on the long-term safety of administering repeated doses of stem cells for liver disease.
- 12:30SPEAKER_00: Which is why the absolute most crucial takeaway is that this is not a cure.
- 12:35SPEAKER_00: Cell therapies are tested as add-ons to standard care, never as replacements.
- 12:40SPEAKER_01: Standard care remains treating the underlying cause, aggressive antivirals for hepatitis, complete cessation of alcohol use.
- 12:47SPEAKER_01: You have to stop the triggers to stop the inflammation.
- 12:50SPEAKER_00: And for end-stage liver disease, a liver transplant remains the main proven medical option.
- 12:55SPEAKER_01: If you or a family member are navigating this, the literature advises bringing grounded questions to a liver specialist.
- 13:02SPEAKER_01: Ask what is causing the injury, what stage it's at, and when a transplant is formally assessed, never stop medicines without a doctor's advice.
- 13:12SPEAKER_00: If we connect this to the bigger picture, this is why the International Society for Stem Cell Research, the ISSCR, urges extreme caution.
- 13:30SPEAKER_00: Until those trials happen, these results are classified as early signals, not clinical answers.
- 13:36SPEAKER_01: So to quickly recap this deep dive, liver disease is a slow march of inflammation and scarring.
- 13:43SPEAKER_01: Stem cells offer a fascinating theoretical way to send calm-down signals to the liver.
- 13:49SPEAKER_00: But human trials are small, flawed, and firmly experimental.
- 13:54SPEAKER_01: It's a complex landscape.
- 13:56SPEAKER_00: It is.
- 13:56SPEAKER_00: But it leaves us with a profound concept to chew on.
- 14:00SPEAKER_00: If our bodies already have a complex language of chemical signals to heal small injuries, and therapies like extracellular vesicles are just trying to mimic that language.
- 14:10SPEAKER_01: The internal messaging system we talked about.
- 14:12SPEAKER_00: Exactly.
- 14:13SPEAKER_00: What if the future of medicine isn't about replacing damaged organs, but simply learning how to speak the body's internal healing language fluently?
- 14:21SPEAKER_01: That is an incredible thought to end on.
- 14:23SPEAKER_01: Thank you for joining us on this deep dive.
- 14:26SPEAKER_01: Keep questioning the headlines and keep learning.